The head of biomedical research at Novartis spoke with STAT about AI, pruning the pipeline, and a potential blockbuster.

Solitary reflection is essential to clinical work, but it can also quietly narrow the range of perspectives a therapist ...

As President Trump hails pricing agreements with the pharmaceutical industry, some biotech companies are worried they have been left out in the cold.

A federal regulatory crackdown on Hims could impact a broader network of compounding pharmacies and telehealth companies.

Even when promising clinical trials exist, and the FDA allows expanded access, rare disease patients like my granddaughter are often left out.

Realfood.gov now features a chatbot tool that’s Elon Musk-affiliated — and rather skeptical of some MAHA initiatives.

A Christian group announces a potentially landmark legal settlement that the ACLU says could establish new federal ...

Over the last few years, Abridge has become one of the leading artificial intelligence companies in health care. It’s got a multi-billion dollar valuation and an ambient scribe used by hundreds of ...

A bipartisan group of US lawmakers took another shot at legislation to boost antibiotic development, and other pharma news.

File this under "If at first you don’t succeed.…" The Trump administration plans another attempt at creating a pilot program ...

Kennedy has made healthy eating a centerpiece of his Make America Healthy Again policy agenda in the last year. He frequently ...

This is the web edition of STAT's D.C. Diagnosis newsletter.